MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Microbot Medical Accounts Receivables 2011-2026 | MBOT
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Microbot Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 159 K | 109 K | 110 K | 54.5 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 159 K | 54.5 K | 108 K |
Quarterly Accounts Receivables Microbot Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.62 K | 2.74 K | 17.2 K | 159 K | 159 K | 159 K | 159 K | 109 K | 109 K | 109 K | 109 K | 110 K | 110 K | 110 K | 110 K | 54.5 K | 54.5 K | 54.5 K | 54.5 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 159 K | 2.62 K | 92.3 K |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M |  USA |
 |
Ekso Bionics Holdings
EKSO
|
7.31 M | $ 10.97 | -2.14 % | $ 26.6 M | USA |
 |
ICU Medical
ICUI
|
181 M | $ 116.64 | -3.61 % | $ 2.87 B | USA |
 |
The Cooper Companies
COO
|
829 M | $ 61.98 | -1.76 % | $ 12.3 B | USA |
 |
Milestone Scientific
MLSS
|
313 K | $ 0.32 | -2.82 % | $ 26.3 M | USA |
 |
iRhythm Technologies
IRTC
|
75.7 M | $ 122.49 | -2.35 % | $ 3.92 B | USA |
 |
Haemonetics Corporation
HAE
|
203 M | $ 59.16 | -1.0 % | $ 2.98 B | USA |
 |
electroCore
ECOR
|
1.03 M | $ 6.26 | 1.79 % | $ 53.1 K | USA |
 |
Repro Med Systems
KRMD
|
6.21 M | $ 4.01 | -1.84 % | $ 185 M | USA |
 |
Pulse Biosciences
PLSE
|
274 K | $ 21.04 | -3.62 % | $ 1.42 B | USA |
 |
Isoray
ISR
|
6 K | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
1.53 B | $ 451.08 | -3.33 % | $ 161 B | USA |
 |
Glaukos Corporation
GKOS
|
39.8 M | $ 116.64 | -2.55 % | $ 5.65 B | USA |
 |
STAAR Surgical Company
STAA
|
50.1 M | $ 26.0 | -2.64 % | $ 1.29 B | USA |
 |
STERIS plc
STE
|
1.04 B | $ 212.66 | -3.39 % | $ 21 B | USA |
 |
Teleflex Incorporated
TFX
|
346 M | $ 135.05 | -0.34 % | $ 6.03 B | USA |
 |
Masimo Corporation
MASI
|
141 M | $ 178.56 | 0.03 % | $ 9.52 B | USA |
 |
InfuSystem Holdings
INFU
|
16.9 M | $ 9.85 | -3.24 % | $ 203 M | USA |
 |
Merit Medical Systems
MMSI
|
204 M | $ 64.8 | -2.91 % | $ 3.83 B | USA |
 |
Utah Medical Products
UTMD
|
3.52 M | $ 66.14 | -0.71 % | $ 214 M | USA |
 |
West Pharmaceutical Services
WST
|
574 M | $ 295.56 | 1.22 % | $ 21.4 B | USA |
 |
Envista Holdings Corporation
NVST
|
430 M | $ 26.23 | -1.02 % | $ 4.41 B | USA |
 |
Retractable Technologies
RVP
|
7.9 M | $ 0.62 | -0.46 % | $ 18.6 M | USA |
 |
Pro-Dex
PDEX
|
16.4 M | $ 50.62 | -1.73 % | $ 166 M | USA |
 |
LeMaitre Vascular
LMAT
|
33.6 M | $ 110.54 | -1.65 % | $ 2.5 B | USA |
 |
Predictive Oncology
POAI
|
32.1 K | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
9.17 M | $ 20.58 | -1.54 % | $ 948 M | USA |
 |
Stereotaxis
STXS
|
5.85 M | $ 1.79 | -4.29 % | $ 163 M | USA |
 |
Baxter International
BAX
|
1.7 B | $ 17.18 | -4.32 % | $ 8.81 B | USA |
 |
ResMed
RMD
|
576 M | $ 212.53 | -2.05 % | $ 31 B | USA |
 |
AtriCure
ATRC
|
66.7 M | $ 27.5 | -3.44 % | $ 1.31 B | USA |
 |
Harvard Bioscience
HBIO
|
16 M | $ 6.27 | -2.79 % | $ 278 M | USA |
 |
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
42.9 M | $ 10.63 | -3.19 % | $ 434 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.99 B | $ 145.61 | -2.6 % | $ 41.9 B | USA |
 |
Nephros
NEPH
|
1.5 M | $ 3.25 | -2.11 % | $ 33.8 M | USA |
 |
OraSure Technologies
OSUR
|
22.2 M | $ 2.97 | -1.33 % | $ 218 M | USA |
 |
Repligen Corporation
RGEN
|
124 M | $ 113.92 | -2.99 % | $ 6.35 M | USA |